The Oxford-AstraZeneca covid vaccine.
Karwai Tang | Getty Images
Denmark has announced that it will temporarily suspend the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford.
The Danish Health Authority said Thursday that it would temporarily halt using the shot in its vaccination program as a precaution “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca.” Its use will be paused for 14 days.
“Against this background, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. At present, it cannot be concluded whether there is a link between the vaccine and the blood clots,” the health authority said in a statement Thursday.
The announcement comes after a similar move in Austria at the start of the week, where authorities are investigating the death of one person and the illness of another after they received doses of the vaccine.
Shares of AstraZeneca slipped 2.4% Thursday.
Austrian health authorities suspended the use of batch ABV5300 of the AstraZeneca vaccine after a person was diagnosed with multiple thrombosis (formation of blood clots within blood vessels) and died 10 days after vaccination, and another was hospitalized with pulmonary embolism after being vaccinated. “The latter is now recovering,” the European Medicines Agency said Wednesday.
However, the EMA added that “there is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.”
The EMA noted that the same batch ABV5300 was delivered to 17 EU countries and comprises 1 million doses of the vaccine.
“Some EU countries have also subsequently suspended this batch as a precautionary measure, while a full investigation is ongoing. Although a quality defect is considered unlikely at this stage, the batch quality is being investigated,” the EMA said.
It added that its safety committee was reviewing the issue and “investigating the cases reported with the batch as well as all other cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination.”
“The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population. As of March 9, “22 cases of thromboembolic events had been reported among the 3 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area,” the EMA said.
U.K. and EU reliance
Late-stage clinical trials found the AstraZeneca/Oxford University shot to have an average efficacy of 70% in protecting against the virus. A more recent study by Oxford researchers found that the Covid vaccine was 76% effective at preventing symptomatic infection for three months after a single dose, and that the efficacy rate actually rose with a longer interval between the first and second doses.
The AstraZeneca/University of Oxford vaccine is being relied upon heavily in the U.K. and European Union’s immunization rollouts. The U.K. has so far vaccinated over 22 million people with a first dose of a coronavirus vaccine and is currently only using the AstraZeneca and Pfizer/BioNTech shot.